Chong Kun Dang Pharmaceutical’s patent involves a pharmaceutical or food composition with enhanced effects using Cinnamomum cassia extract. The method includes pretreating the extract with a non-polar solvent and extracting it with a polar solvent. The claim focuses on a method for improving gastritis or peptic ulcer by administering this composition. GlobalData’s report on Chong Kun Dang Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Chong Kun Dang Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents.
Pharmaceutical composition for gastritis/peptic ulcer treatment using cinnamomum cassia extract
A recently granted patent (Publication Number: US11918618B2) outlines a method for improving or treating gastritis or peptic ulcers by administering a composition containing an extract of Cinnamomum cassia. The extract is prepared through a specific method involving immersing the plant into ethyl acetate, removing the ethyl acetate, and then extracting the plant with water. This unique process aims to reduce cinnamic aldehyde and 2-methoxycinnamic aldehyde in the extract, potentially enhancing its therapeutic properties for gastrointestinal conditions.
The patent claims specify that the composition can be in the form of a pharmaceutical composition or food composition, including health functional food, health supplementary food, or functional food. It further highlights that the method is particularly targeted towards treating stomach ulcers or duodenal ulcers. The administration of the composition can be done once or multiple times in divided doses, with the daily dose of the Cinnamomum cassia water extract ranging from 9.7 to 2,919 mg. These precise details provide a framework for utilizing the extract effectively in addressing gastritis and peptic ulcers, potentially offering a new avenue for therapeutic interventions in these conditions.
To know more about GlobalData’s detailed insights on Chong Kun Dang Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

